Obesity Epidemic: Pharmaceutical Weight Loss

R I Med J (2013). 2017 Mar 1;100(2):18-20.

Abstract

Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30.0 kg/m2. Over the past few years, the concept of prevention has gained increased awareness, thus leading to the development of additional pharmaceutical options for the treatment of obesity since 2012. Treating obesity revolves around an individualized, multi-disciplinary approach with additional focus on a healthy and supportive lifestyle to maintain the weight loss. [Full article available at http://rimed.org/rimedicaljournal-2017-03.asp].

Keywords: anti-obesity therapies; morbid obesity; obesity; overweight; weight-loss medications.

MeSH terms

  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / therapeutic use*
  • Benzazepines / adverse effects
  • Benzazepines / therapeutic use
  • Body Mass Index
  • Bupropion / adverse effects
  • Bupropion / therapeutic use
  • Drug Combinations
  • Fructose / adverse effects
  • Fructose / analogs & derivatives
  • Fructose / therapeutic use
  • Humans
  • Lactones / adverse effects
  • Lactones / therapeutic use
  • Liraglutide / adverse effects
  • Liraglutide / therapeutic use
  • Naltrexone / adverse effects
  • Naltrexone / therapeutic use
  • Obesity / drug therapy*
  • Orlistat
  • Phentermine / adverse effects
  • Phentermine / therapeutic use
  • Weight Loss / drug effects*

Substances

  • Anti-Obesity Agents
  • Benzazepines
  • Drug Combinations
  • Lactones
  • Qsymia
  • bupropion hydrochloride, naltrexone hydrochoride drug combination
  • Bupropion
  • Fructose
  • Naltrexone
  • lorcaserin
  • Liraglutide
  • Orlistat
  • Phentermine